← Leaderboards
Christopher Cassa
Brigham And Women'S Hospital
$5,157,160
Attributed
$5,623,171
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,623,171 · 6
By mechanism
R01$3,485,344 · 1
R21$872,670 · 2
R00$746,997 · 1
R56$300,000 · 1
K99$218,160 · 1
Top collaborators
- Richard I Sherwood4 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Kenneth M Kaye$21,944,697
- Mark W Feinberg$27,862,974
- Geoffrey Young$3,819,165
- Danielle S Bitterman$1,164,403
- Kejun Ying$124,333
Others in their field
Top investigators on “Variant”
- Richard A Gibbs · Baylor College Of Medicine$367,607,426
- Richard K. Wilson · Washington University$295,336,569
- Stacey Gabriel · Massachusetts Institute Of Technology$169,231,712
- David Heimbrook · Leidos Biomedical Research, Inc.$125,120,179
- Heidi L Rehm · Broad Institute, Inc.$96,250,516
- Margaret A Pericak-Vance · Doheny Eye Institute$83,999,609
Research focus
VariantStructurePathogenicityGenomicsClassificationGenetic VariantAlgorithmsClinical RiskGeneticEpidemiologyLaboratoriesDatabasesMedical GeneticsGenesCohortMedicalClinical ApplicationPositioning AttributeHypertrophic CardiomyopathyNovel StrategiesPenetranceCodeEvaluationMutation
Grant awards (15)
From Text to Translation: Using Language Models to Resolve and Classify Variants$240,647
R21 · FY2025 · HG · contact PI
Integrative computational-experimental approaches to stratify monogenic disease risk$300,000
R56 · FY2023 · HG · contact PI
Integrated pathogenicity assessment of clinically actionable genetic variants$692,441
R01 · FY2022 · HG · contact PI
Integrated pathogenicity assessment of clinically actionable genetic variants$692,441
R01 · FY2021 · HG · contact PI
Integrated pathogenicity assessment of clinically actionable genetic variants$692,441
R01 · FY2020 · HG · contact PI
Correcting genetic disorders using predictable CRISPR/Cas9-induced exon skipping$223,750
R21 · FY2020 · HG
Urgent Supplement: Correcting genetic disorders using predictable CRISPR/Cas9-induced exon skipping$139,773
R21 · FY2020 · HG
Integrated pathogenicity assessment of clinically actionable genetic variants$692,441
R01 · FY2019 · HG · contact PI
Correcting genetic disorders using predictable CRISPR/Cas9-induced exon skipping$268,500
R21 · FY2019 · HG
Integrated pathogenicity assessment of clinically actionable genetic variants$715,580
R01 · FY2018 · HG · contact PI
Clinical prioritization of reported disease variants in asymptomatic individuals$248,999
R00 · FY2017 · HG · contact PI
Clinical prioritization of reported disease variants in asymptomatic individuals$248,999
R00 · FY2016 · HG · contact PI
Clinical prioritization of reported disease variants in asymptomatic individuals$248,999
R00 · FY2015 · HG · contact PI
Clinical prioritization of reported disease variants in asymptomatic individuals$109,080
K99 · FY2014 · HG · contact PI
Clinical prioritization of reported disease variants in asymptomatic individuals$109,080
K99 · FY2013 · HG · contact PI